July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Innovative high-frequency electrotherapy device Rexon-Eye successfully treats Meibomian gland disease patients
Author Affiliations & Notes
  • Alfredo Ruggeri
    Resono Ophthalmic, Italy
    Dept of Information Engineering, University of Padua, Padua, Italy
  • Annalisa Colucci
    Ospedale San Raffaele, Milano, Italy
  • Marco Barbariga
    Ospedale San Raffaele, Milano, Italy
  • Paolo Rama
    Ospedale San Raffaele, Milano, Italy
  • Giulio Ferrari
    Ospedale San Raffaele, Milano, Italy
  • Footnotes
    Commercial Relationships   Alfredo Ruggeri, Resono Ophthalmic (I), Resono Ophthalmic (P), Resono Ophthalmic (S); Annalisa Colucci, None; Marco Barbariga, None; Paolo Rama, None; Giulio Ferrari, Resono Ophthalmic (F)
  • Footnotes
    Support  Resono Ophthalmic research grant
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6749. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alfredo Ruggeri, Annalisa Colucci, Marco Barbariga, Paolo Rama, Giulio Ferrari; Innovative high-frequency electrotherapy device Rexon-Eye successfully treats Meibomian gland disease patients. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6749.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We investigated the safety and efficacy of an innovative treatment in twenty-five patients affected by Meibomian gland disease (MGD). The treatment consists in the administration of a specific low-power, high-frequency electrical current using the Rexon-Eye device.

Methods : Twenty-five consecutive MGD patients were recruited. Therapy was administered with the Rexon-Eye device (Resono Ophthalmic, Trieste, Italy; patented), which applies an electrical current with a specific spectrum of frequencies (4-64 MHz, Quantum Molecular Resonance, QMR®). Patients were administered one 20 min treatment per week, for 4 weeks. Patients were examined at baseline and one month after the last treatment, by measuring: corneal fluorescein staining with Oxford scheme (CFS), Ocular Surface Disease Index (OSDI) score, tear break-up time (TBUT), Meibomian gland secretion score (MGSS), number of expressible Meibomian glands (MGNR), Schirmer test (SCHIRMER). Safety was investigated assessing Best Spectacle Corrected Visual Acuity (BSCVA) and intraocular pressure (IOP).

Results : All the clinical endpoints improved significantly on average and in almost all of the patients. Results for CFS, OSDI, TBUT, MGSS, MGNR, and SCHIRMER are reported in Fig.1 for 24 patients (one patient dropped out of the study). No adverse events nor changes in BSCVA and IOP were observed.

Conclusions : The Rexon-Eye device with its QMR® treatment is effective in ameliorating a number of ocular parameters associated with MGD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Fig 1: Results for CFS, OSDI, TBUT, MGSS, MGNR, and SCHIRMER for 24 patients. Statistical significance in difference: **** p<0.0001; *** p = 0.0003; ** p=0.01.
1: MGSS and MGNR were measured as per Nichols et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest Ophthalmol Vis Sci 2011.

Fig 1: Results for CFS, OSDI, TBUT, MGSS, MGNR, and SCHIRMER for 24 patients. Statistical significance in difference: **** p<0.0001; *** p = 0.0003; ** p=0.01.
1: MGSS and MGNR were measured as per Nichols et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest Ophthalmol Vis Sci 2011.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×